Literature DB >> 24696721

Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature.

Peihong Hsu1, Tianyu Yang1, Silvat Sheikh-Fayyaz1, Judith Brody1, Jela Bandovic1, Sarma Roy1, Jordan Laser1, Jonathan E Kolitz2, Craig Devoe2, Xinmin Zhang1.   

Abstract

We present two rare cases of in situ mantle cell lymphoma ("in situ MCL") and three cases of MCL with mantle zone growth pattern (MCL-MZGP). The patients include four males and one female, with a median age of 66 years (range, 52 to 86 years). Two present with isolated lymphadenopathy and three with multiple lymphadenopathy. At presentation, the complete blood count (CBC) and serum lactate dehydrogenase (LDH) are normal in all cases. Histologic examination reveals an in situ pattern in two cases and a mantle zone growth pattern in three cases. The staging bone marrow biopsies show minimal involvement by lymphoma in one case and no morphologic evidence of lymphoma in four cases. All cases are positive for cyclin D1, including two with typical MCL phenotype and three with CD5-negativity. Four out of five cases express kappa light chain. FISH study for t(11;14) is performed in three cases, of which one is positive and two are inconclusive. For four patients with a median follow-up of 38 months, three are in clinical remission and one has persistent disease. In conclusion, the "in situ MCL" is associated with incidental finding, indolent clinical course and lower tumor burden. The predominant usage of kappa light chain and frequent CD5-negativity observed in our cases are unusual. We review the clinical and laboratory features of "in situ MCL" cases in the literature.

Entities:  

Keywords:  Mantle cell lymphoma; in situ mantle cell lymphoma; t(11;14)

Mesh:

Year:  2014        PMID: 24696721      PMCID: PMC3971307     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

1.  VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

Authors:  Dirk Kienle; Alexander Kröber; Tiemo Katzenberger; German Ott; Elke Leupolt; Thomas F E Barth; Peter Möller; Axel Benner; Annett Habermann; Hans Konrad Müller-Hermelink; Martin Bentz; Peter Lichter; Hartmut Dōhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

2.  Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.

Authors:  Shi Wang; Alexander Tzankov; Zijun Y Xu-Monette; Sylvia Hoeller; Sa A Wang; Kristy L Richards; Shanxiang Zhang; Jonathan W Said; L Jeffrey Medeiros; Ken H Young
Journal:  Hum Pathol       Date:  2013-09-24       Impact factor: 3.466

Review 3.  Mantle cell lymphoma-- an entity comes of age.

Authors:  D D Weisenburger; J O Armitage
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

4.  Mantle cell lymphoma: a clinicopathologic study of 80 cases.

Authors:  L H Argatoff; J M Connors; R J Klasa; D E Horsman; R D Gascoyne
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants.

Authors:  A Majlis; W C Pugh; M A Rodriguez; W F Benedict; F Cabanillas
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

6.  Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?

Authors:  Blanca Espinet; Francesc Solé; Carme Pedro; Mar Garcia; Beatriz Bellosillo; Marta Salido; Lourdes Florensa; Francisca I Camacho; Teresa Baró; Josep Lloreta; Sergi Serrano
Journal:  Hum Pathol       Date:  2005-11       Impact factor: 3.466

7.  CD5- mantle cell lymphoma.

Authors:  Zach Liu; Henry Y Dong; Wojciech Gorczyca; Patricia Tsang; Patti Cohen; Christine F Stephenson; Carol S Berger; C Daniel Wu; James Weisberger
Journal:  Am J Clin Pathol       Date:  2002-08       Impact factor: 2.493

Review 8.  The cellular origin of mantle cell lymphoma.

Authors:  Francesco Bertoni; Maurilio Ponzoni
Journal:  Int J Biochem Cell Biol       Date:  2007-05-10       Impact factor: 5.085

9.  Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders.

Authors:  Scott J Rodig; Barbara M Healey; Geraldine S Pinkus; Frank C Kuo; Paola Dal Cin; Jeffery L Kutok
Journal:  Cancer Genet Cytogenet       Date:  2006-11

10.  Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes.

Authors:  Laurentia Nodit; David W Bahler; Samuel A Jacobs; Joseph Locker; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2003-10       Impact factor: 3.466

View more
  4 in total

1.  CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.

Authors:  Arshia Soleimani; Alba Navarro; Delong Liu; Sarah E M Herman; Shih-Sung Chuang; Irma Slavutsky; Marina Narbaitz; Hana Safah; John Schmieg; John Lefante; Mark Roschewski; Wyndham H Wilson; Adrian Wiestner; Nakhle S Saba
Journal:  Leuk Lymphoma       Date:  2021-11-15

2.  A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature.

Authors:  Josephine Taverna; Anju Nair; Seongseok Yun; Spencer Paulson; Jonathan H Schatz; Daniel Persky; Deborah Fuchs; Soham Puvvada
Journal:  Case Rep Hematol       Date:  2014-11-16

3.  High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.

Authors:  Philippa Li; Ji Yuan; Fahad Shabbir Ahmed; Austin McHenry; Kai Fu; Guohua Yu; Hongxia Cheng; Mina L Xu; David L Rimm; Zenggang Pan
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

4.  An overlapping case of in situ mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma.

Authors:  Ryota Matsuoka; Noriaki Sakamoto; Mamiko Sakata-Yanagimoto; Shigeru Chiba; Masayuki Noguchi; Naoya Nakamura
Journal:  J Clin Exp Hematop       Date:  2020-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.